ATE238056T1 - Pharmazeutische kombinationspräparate in fester form enthaltend carvedilol und hydrochlorothiazid - Google Patents

Pharmazeutische kombinationspräparate in fester form enthaltend carvedilol und hydrochlorothiazid

Info

Publication number
ATE238056T1
ATE238056T1 AT99957320T AT99957320T ATE238056T1 AT E238056 T1 ATE238056 T1 AT E238056T1 AT 99957320 T AT99957320 T AT 99957320T AT 99957320 T AT99957320 T AT 99957320T AT E238056 T1 ATE238056 T1 AT E238056T1
Authority
AT
Austria
Prior art keywords
hydrochlorothiazide
solid form
pharmaceutical combination
form containing
combination preparations
Prior art date
Application number
AT99957320T
Other languages
English (en)
Inventor
Rudolf Heller
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8233041&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE238056(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE238056T1 publication Critical patent/ATE238056T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT99957320T 1998-11-27 1999-11-20 Pharmazeutische kombinationspräparate in fester form enthaltend carvedilol und hydrochlorothiazid ATE238056T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98122489 1998-11-27
PCT/EP1999/008972 WO2000032174A2 (en) 1998-11-27 1999-11-20 Pharmaceutical combination preparations of carvedilol and hydrochlorothiazide

Publications (1)

Publication Number Publication Date
ATE238056T1 true ATE238056T1 (de) 2003-05-15

Family

ID=8233041

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99957320T ATE238056T1 (de) 1998-11-27 1999-11-20 Pharmazeutische kombinationspräparate in fester form enthaltend carvedilol und hydrochlorothiazid

Country Status (22)

Country Link
US (3) US6403579B1 (de)
EP (1) EP1131072B1 (de)
JP (2) JP2002531395A (de)
KR (1) KR100421347B1 (de)
CN (1) CN1184971C (de)
AR (1) AR020287A1 (de)
AT (1) ATE238056T1 (de)
AU (1) AU765977B2 (de)
BR (1) BR9915610A (de)
CA (1) CA2352361C (de)
CO (1) CO5011053A1 (de)
DE (1) DE69907252T2 (de)
DK (1) DK1131072T3 (de)
ES (1) ES2195638T3 (de)
MY (1) MY121831A (de)
PE (1) PE20001302A1 (de)
PT (1) PT1131072E (de)
TR (3) TR200200982T2 (de)
TW (1) TWI228414B (de)
UY (1) UY25821A1 (de)
WO (1) WO2000032174A2 (de)
ZA (1) ZA200104280B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
WO2002065834A2 (en) * 2000-10-24 2002-08-29 Smithkline Beecham Corporation Novel formulations of carvedilol
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
IN191028B (de) * 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
WO2003092622A2 (en) * 2002-04-30 2003-11-13 Sb Pharmco Puerto Rico Inc. Carvedilol monocitrate monohydrate
EP1539140A4 (de) 2002-06-27 2005-12-07 Sb Pharmco Inc Carvedilolhydobromid
BR0312102A (pt) * 2002-06-27 2007-05-29 Sb Pharmco Inc sais de fosfato de carvedilol e/ou seus solvatos, composições correspondentes, e/ou métodos de tratamento
EP1562552A1 (de) 2002-11-08 2005-08-17 Egalet A/S Zusammensetzung zur kontrollierten wirkstoffabgabe von carvedilol
EP1610767B1 (de) 2003-03-26 2011-01-19 Egalet A/S Morphin-system mit kontrollierter freisetzung
WO2004094378A1 (en) * 2003-04-21 2004-11-04 Matrix Laboratories Ltd Process for the preparation of carvedilol form-ii
AU2003272851A1 (en) * 2003-09-26 2005-04-14 Shuyi Zhang Sustained release preparation containing hydrochlorothiazide
JP2007512372A (ja) 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール塩、対応する組成物、送達および／または治療方法
US20050169994A1 (en) * 2003-11-25 2005-08-04 Burke Matthew D. Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
US8734850B2 (en) * 2003-11-25 2014-05-27 Flamel Technologies Oral medicinal product with modified release of at least one active principle in multimicrocapsular form
CN1886132A (zh) * 2003-12-02 2006-12-27 尼科克斯公司 用作降压药的卡维地洛和其它β阻断剂的硝基氧基衍生物
EP2281556A1 (de) * 2005-02-25 2011-02-09 F. Hoffmann-La Roche AG Tablette mit verbesserter Arzneimittelsubstanzdispersibilität
DE602007012692D1 (de) 2006-06-16 2011-04-07 Lek Pharmaceuticals Pharmazeutische zusammensetzung mit hydrochlorothiazid und telmisartan
GB0612540D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
WO2008114276A1 (en) * 2007-03-16 2008-09-25 Lupin Limited Novel oral controlled release composition of carvedilol
EP2155167A2 (de) 2007-06-04 2010-02-24 Egalet A/S Pharmazeutische zusammensetzungen mit gesteuerter freisetzung für verlängerte wirkung
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
US20130121916A1 (en) * 2010-03-10 2013-05-16 Sergio Baroni Compositions for Colon Lavage and Methods of Making and Using Same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
FR2643556B1 (fr) * 1989-02-27 1993-03-05 Sanofi Sa Composition pharmaceutique a liberation prolongee d'acide valproique
PL169106B1 (pl) * 1991-01-30 1996-06-28 Wellcome Found Sposób wytwarzania dyspergowalnej w wodzie tabletki PL PL PL PL PL PL PL
DE69222006T2 (de) * 1991-10-30 1998-01-22 Glaxo Group Ltd Mehrschichtzusammensetzungen enthaltend Histamin- oder Serotonin- Antagonisten
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
FR2752162B1 (fr) * 1996-08-07 1998-11-06 Jouveinal Lab Comprime de maleate de trimebutine pellicule
DE19637082A1 (de) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida

Also Published As

Publication number Publication date
EP1131072B1 (de) 2003-04-23
CN1184971C (zh) 2005-01-19
CN1328460A (zh) 2001-12-26
AU1506500A (en) 2000-06-19
TWI228414B (en) 2005-03-01
KR20010080578A (ko) 2001-08-22
US20020052367A1 (en) 2002-05-02
MY121831A (en) 2006-02-28
CO5011053A1 (es) 2001-02-28
TR200200981T2 (tr) 2002-06-21
US20040087578A1 (en) 2004-05-06
CA2352361C (en) 2007-01-02
ZA200104280B (en) 2002-08-26
KR100421347B1 (ko) 2004-03-06
AU765977B2 (en) 2003-10-09
DK1131072T3 (da) 2003-08-11
DE69907252T2 (de) 2004-01-29
CA2352361A1 (en) 2000-06-08
JP2002531395A (ja) 2002-09-24
TR200101470T2 (tr) 2001-11-21
UY25821A1 (es) 2001-07-31
BR9915610A (pt) 2001-08-14
TR200200982T2 (tr) 2002-06-21
PT1131072E (pt) 2003-08-29
US6403579B1 (en) 2002-06-11
AR020287A1 (es) 2002-05-02
WO2000032174A2 (en) 2000-06-08
WO2000032174A3 (en) 2000-11-16
PE20001302A1 (es) 2000-11-30
DE69907252D1 (de) 2003-05-28
ES2195638T3 (es) 2003-12-01
EP1131072A2 (de) 2001-09-12
JP2007077160A (ja) 2007-03-29

Similar Documents

Publication Publication Date Title
ATE238056T1 (de) Pharmazeutische kombinationspräparate in fester form enthaltend carvedilol und hydrochlorothiazid
CY2013032I2 (el) Συζυγη της εξενδινης-4 και η φαρμακευτικη τους χρηση
ATE446749T1 (de) Feste orale dosierungsformen enthaltend valsartan und hydrochlorothiazide
ATE431830T1 (de) Glucopyranosylpyrazolderivate und deren verwendung in arzneimitteln
CY2009015I2 (el) Φαρμακευτικος συνδυασμος αιθινυλεστραδιολης και δροπιρενονης για χρηση ως αντισυλληπτικο
EE200100568A (et) 6-alkenüül-, 6-alkünüül- ja 6-epoksüepotilooni derivaadid, nende valmistamismeetod ja kasutamine farmatseutilistes preparaatides
EE200000723A (et) Asendatud indolinoonid, nende valmistamine ja nende kasutamine ravimitena
TR199500832A2 (tr) Benzimidazol türevleri ve bunlarin medikal terapide kullanimi ve bunlari iceren farmasötik formülasyonlar.
ATE243516T1 (de) Amoxicillin und clavulanat enthaltende arzneizubereitungen
ID22565A (id) Penggunaan nanodispersi dalam formulasi akhir obat
DE69828895D1 (de) Alpha-aryl-n-alkylnitrone sowie diese enthaltende pharmazeutische zubereitungen
PT1212317E (pt) Derivados de indole e sua utilizacao no tratamento de osteoporose entre outras aplicacoes
ATE383868T1 (de) Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka
DE60322454D1 (de) Pharmazeutische Zusammensetzungen zur oralen und topischen Verabreichung
ATE285762T1 (de) Kombinationspräparate enthaltend statin und karboxyalkyläther
DE69415570D1 (de) Esculetin Derivate und pharmazeutische Zusammenstellung
ATE310726T1 (de) Pyridin-derivate und diese enthaltende pharmazeutische mittel
ATE228839T1 (de) Tizoxanide und nitazoxanide enthaltende pharmazeutische zusammensetzungen
DE69907735D1 (de) Melatoninderivate und diese enthaltende pharmazeutische zubereitung
DE50006823D1 (de) Kosmetische und/oder pharmazeutische zubereitungen
DE69800970D1 (de) Pyridinderivate und sie enthaltende pharmazeutische zubereitungen
DE69813624D1 (de) Gemisch und pharmazeutische zubereitung enthaltend z-4-hydroxytamoxifen und cyclodextrin
IT1291823B1 (it) Composti pseudo-peptidici, loro preparazione ed uso in formulazioni farmaceutiche
DE60034963D1 (de) Heterocyclische derivate und arzneistoffe
ATE338548T1 (de) Pyridoindolonderivate und antikrebsmittel enthaltende pharmazeutische mischungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1131072

Country of ref document: EP

EETN Declaration of nullification in part